Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome

New England Journal of Medicine

Volumn 371, Issue 16, 2014, Pages 1554-

  Hidalgo, Luis G ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT; PHOSPHOLIPID ANTIBODY; TARGET OF RAPAMYCIN KINASE;

ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; DRUG EFFICACY; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LETTER; DRUG ANTAGONISM; FEMALE; MALE; METABOLISM; NOTE; VASCULAR ENDOTHELIUM;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84908059841     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1410247     Document Type: Letter

References (4)

1. Flechner SM. Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors. Transplantation 2009;87:Suppl:S1-S6.
2. Tait BD, Süsal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013;95:19-47.
3. Hill GS, Nochy D, Bruneval P, et al. Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. J Am Soc Nephrol 2011;22:975-83.
4. Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012;12: 1192-8.